Transaction DateRecipientSharesTypePriceValue
23rd July 2020Michael J. Mc Elhaugh20,000Open or private sale$5.01$100,200.00
Arbutus Biopharma
Arbutus Biopharma logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 5/10.


Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for chronic Hepatitis B virus infection. The company is headquartered in Burnaby, Canada.


Ticker: ABUS
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1447028
Employees: 80
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $46 M (44%)
Assets, Current: $86 M (-8%)
Property, Plant and Equipment, Net: $8 M (-10%)
Other Assets, Noncurrent: $173 Th (-40%)
Assets: $98 M (-7%)
Liabilities, Current: $6 M (-19%)
Liabilities: $32 M (-2%)
Common Stock, Value, Issued: $916 M (1%)
Common Stock, Shares, Issued: $71 M (9%)
Retained Earnings (Accumulated Deficit): $1 B (3%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $48 M (0%)
Stockholders' Equity (Parent): $66 M (0%)
Liabilities and Equity: $98 M (-7%)
Research and Development: $10 M (-49%)
General and Administrative Expenses: $4 M (-49%)
Restructuring Charges: $7 Th (-89%)
Operating Income/Loss: $13 M (-50%)
Other Income, net: $946 Th (-43%)